Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival

[1] Marion S(2018)Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review Crit Rev Oncol Hematol 123 21-41

[2] Sophie G(2017)Surrogate endpoints for overall survival in lung cancer trials: a review Expert Rev Anticancer Ther 5 447-454

[3] Anoine I(2019)Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer Breast Cancer Res Treat 176 495-506

[4] Frederic F(2018)Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer Oncol Targets Ther 11 3059-3063

[5] Virginie W(2009)Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 101 1642-1649

[6] Franck B(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-246

[7] Michael PL(2017)Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer N Engl J Med 377 829-838

[8] Sarah B(2011)RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 1252-1260

[9] Stephanie H(2017)Olaparib for metastatic breast cancer in patients with a germline BRCA mutation N Engl J Med 377 523-533

[10] Giuseppe C(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019

[1] Marion S(2018)Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review Crit Rev Oncol Hematol 123 21-41

[2] Sophie G(2017)Surrogate endpoints for overall survival in lung cancer trials: a review Expert Rev Anticancer Ther 5 447-454

[3] Anoine I(2019)Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer Breast Cancer Res Treat 176 495-506

[4] Frederic F(2018)Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer Oncol Targets Ther 11 3059-3063

[5] Virginie W(2009)Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 101 1642-1649

[6] Franck B(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-246

[7] Michael PL(2017)Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer N Engl J Med 377 829-838

[8] Sarah B(2011)RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 1252-1260

[9] Stephanie H(2017)Olaparib for metastatic breast cancer in patients with a germline BRCA mutation N Engl J Med 377 523-533

[10] Giuseppe C(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019